Track the 셀루메드 stock price and the full insider trade history of the company, a listed issuer based in South Korea. Shares are quoted on KR KR, under the authority of DART (FSS). Operating in the Health Care sector, 셀루메드 has logged 37 insider filings. Market capitalisation: €83.9bn. The latest transaction was disclosed on 23 March 2026 (Other). Among the most active insiders: 인스코비. The full history is openly available.
37
Insider Decl.
n/a
Thresholds
n/a
20 ops.
Buy Volume
n/a
4 ops.
Sell Volume
19Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 25,855 of 28,016 companies
19.2
score / 100
Value
24
Quality
15
FCF yld-4.9%
Earn yld-2.7%
EV/EBITDA·
ROE-14%
Gross mgn4.7%
Net mgn-1.6%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
셀루메드 operates in the healthcare and pharmaceutical sector, listed on the XKRX market. The company focuses on developing innovative healthcare solutions.